Free tool
FAERS Monitor: Sympazan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210833 or its brand name (Sympazan, Clobazam). Reports on generic versions are filed under their own applications.
Reports
17,678
Serious
15,318
87% of reports
Hospitalization
6,630
Death reported
1,245
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure3,075
- drug ineffective2,717
- off label use1,949
- somnolence1,356
- drug interaction1,059
- epilepsy810
- condition aggravated760
- fatigue742
- status epilepticus625
- multiple-drug resistance584
- generalised tonic-clonic seizure530
- foetal exposure during pregnancy520
- toxicity to various agents476
- fall469
- decreased appetite460
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 73 |
| 2006 | 69 |
| 2007 | 84 |
| 2008 | 111 |
| 2009 | 127 |
| 2010 | 168 |
| 2011 | 127 |
| 2012 | 299 |
| 2013 | 273 |
| 2014 | 296 |
| 2015 | 392 |
| 2016 | 385 |
| 2017 | 542 |
| 2018 | 894 |
| 2019 | 1,315 |
| 2020 | 1,354 |
| 2021 | 2,018 |
| 2022 | 1,616 |
| 2023 | 1,958 |
| 2024 | 2,167 |
| 2025 | 1,945 |
| 2026 | 1,418 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,481 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple-drug resistanceSignal | 584 | 275.8 | 252.3 | 129,600 |
| status epilepticusSignal | 625 | 69.7 | 64.3 | 39,913 |
| generalised tonic-clonic seizureSignal | 530 | 39.3 | 36.1 | 19,144 |
| seizureSignal | 3,075 | 32.5 | 31.5 | 91,896 |
| epilepsySignal | 810 | 32.4 | 30.2 | 23,963 |
| somnolenceSignal | 1,356 | 8.1 | 7.7 | 8,402 |
| drug interactionSignal | 1,059 | 8.0 | 7.5 | 6,473 |
| foetal exposure during pregnancySignal | 520 | 7.7 | 7.0 | 2,994 |
| toxicity to various agentsSignal | 476 | 3.4 | 3.1 | 793 |
| condition aggravatedSignal | 760 | 3.0 | 2.8 | 1,009 |
| off label useSignal | 1,949 | 2.7 | 2.5 | 2,086 |
| drug ineffectiveSignal | 2,717 | 2.5 | 2.4 | 2,495 |
| decreased appetiteSignal | 460 | 2.4 | 2.2 | 362 |
| fall | 469 | 1.7 | 1.5 | 130 |
| fatigue | 742 | 1.1 | 1.1 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.